US Patent Issued to Stealth BioTherapeutics on March 18 for "Analogs that target mitochondrial diseases" (Massachusetts, Connecticut Inventors)

ALEXANDRIA, Va., March 19 -- United States Patent no. 12,252,554, issued on March 18, was assigned to Stealth BioTherapeutics Inc. (Needham, Mass.).

"Analogs that target mitochondrial diseases" was invented by Guozhu Zheng (Lexington, Mass.), Mark J. Bamberger (South Glastonbury, Conn.) and Inese Smukste (Weston, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed are analogs of elamipretide (MTP-131). The compounds are useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction."

The patent was filed on Nov. 19, 2019, under Application No. 17/414,168.

*For further information, including images, charts and tables, pl...